BeOne Medicines And Revolution Medicines Form Clinical Collaboration To Evaluate Drug Combinations Using Select Clinical-Stage Oncology Assets From BeOne With Any Of Revolution’s Four Clinical RAS(ON) Inhibitors

Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.

Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms

BeOne Medicines Inks Voluntary Agreement With U.S. Government To Expand Access To Cancer Drugs For American Patients

BeOne Medicines' Topline Data From Second Interim Analysis of Phase 3 HERIZON-GEA-01 Trial of ZIIHERA (zanidatamab) Plus Chemo, With and Without TEVIMBRA (tislelizumab) Show Statistically Significant and Clinically Meaningful Improvement in Overall Survival Trastuzumab Plus Chemo for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma

Reported Earlier, Revolution Medicines Lung Cancer Drug Shows 42% Response Rate In Early Trial

Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Revolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival in a docetaxel-naïve subgroup, with a manageable safety profile. Results support the ongoing Phase 3 RASolve 301 trial.